Related Experiment Video
Updated: Aug 5, 2026
09:02
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Cell Membrane-Modified Lipid Nanoparticle Enhanced Glioblastoma Immunotherapy via Metabolism Reprogramming and
Pengxuan Zhao1,2, Yu Tian3, Weigang Yuan4
1Hainan Provincial Key Laboratory of Research and Development on Tropical Herbs, Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, School of Pharmacy, Hainan Medical University, Haikou 571199, China.
Pharmaceutics
|July 28, 2026
Summary
This study developed a novel nanoparticle system to target glioblastoma (GBM). It inhibits indoleamine 2,3-dioxygenase-1 (IDO1) and triggers pyroptosis, enhancing antitumor immunity for effective GBM immunotherapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Glioblastoma (GBM) exhibits an immunosuppressive tumor microenvironment (TME) hindering immunotherapy.
- Tryptophan metabolism, particularly indoleamine 2,3-dioxygenase-1 (IDO1) activity, significantly contributes to GBM's immunosuppressive TME.
- Gasdermin B (GSDMB)-mediated pyroptosis presents a novel mechanism for immune response activation.
Purpose of the Study:
- To develop a targeted delivery system for glioblastoma immunotherapy.
- To investigate the combined effects of IDO1 inhibition and pyroptosis induction in remodeling the GBM TME.
- To create a novel therapeutic strategy for glioblastoma.
Main Methods:
- Preparation of a GBM cell membrane (CM)-modified lipid nanoparticle (CMLNP) for targeted delivery.
- Delivery of CRISPR/Cas9 components for IDO1 gene knockdown.
- Delivery of GSDMB N-terminal domain (GSDMB^NT) mRNA to induce pyroptosis.
Main Results:
- CM modification provided tumor homing and homotypic targeting capabilities for the nanoparticle.
- IDO1 gene knockdown effectively remodeled the immunosuppressive TME.
- GSDMB^NT mRNA successfully triggered pyroptosis, eliciting a robust immune response.
Conclusions:
- The developed CMLNP system demonstrates potent antitumor immunity against glioblastoma.
- This approach offers a promising and novel strategy for enhancing glioblastoma immunotherapy by targeting the TME and immune activation.
